Work

Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.5502

Authors: Rodney Paul Rocconi, Sharad A. Ghamande, Minal A. Barve, Erin E. Stevens, Phylicia Aaron, Laura Stanbery, Ernest Bognar, Luisa Manning, John J. Nemunaitis, David M. O'Malley, Thomas J. Herzog, Bradley J. Monk, Robert L. Coleman, The Vigil Team

Institutions: University of South Alabama, Augusta University, Texas Oncology, Billings Clinic, Gradalis (United States), The Ohio State University Wexner Medical Center, University of Cincinnati, The US Oncology Network, University of Arizona College of Medicine- Phoenix

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3166545814

Cites:

Cited by: 4

Related to: 10